FDA approves Roche Tecentriq combination as first adjuvant immunotherapy for stage III dMMR colon cancer
The FDA has approved Roche's Tecentriq-based chemotherapy regimen as the first adjuvant immunotherapy option for eligible patients with stage III mismatch repair-deficient colon cancer.
The approval covers Tecentriq (atezolizumab) and Tecentriq Hybreza in combination with fluoropyrimidine and oxaliplatin chemotherapy for adjuvant treatment of stage III dMMR colon cancer.
In the Phase III ATOMIC trial, the immunotherapy combination reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone, establishing a new treatment option following surgery.
Field | Content |
Article Type | Approvals |
Drug Names | Tecentriq; Tecentriq Hybreza |
Generic Name | Atezolizumab |
Company | Roche |
Regulatory Authority | U.S. Food and Drug Administration |
Approval Type | New adjuvant treatment indication |
Indication | Stage III mismatch repair-deficient colon cancer |
Patient Population | Eligible patients with stage III dMMR colon cancer |
Therapy Area | Oncology; colorectal cancer |
Technology/Modality | PD-L1 checkpoint inhibitor immunotherapy |
Approved Regimen | Atezolizumab or atezolizumab and hyaluronidase-tqjs in combination with fluoropyrimidine and oxaliplatin chemotherapy |
Treatment Setting | Adjuvant treatment following surgery |
Clinical Study | Phase III ATOMIC |
Key Clinical Finding | 50% reduction in the risk of disease recurrence or death compared with chemotherapy alone |
Biomarker | Mismatch repair deficiency (dMMR) |
Geography | United States |
What Happened | The FDA approved Tecentriq and Tecentriq Hybreza in combination with fluoropyrimidine and oxaliplatin chemotherapy for adjuvant treatment of eligible patients with stage III dMMR colon cancer. |
Why It Matters | The decision establishes the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer and introduces a biomarker-directed treatment option in this setting. |
Supporting Context | The Phase III ATOMIC study demonstrated a 50% reduction in the risk of recurrence or death with the atezolizumab-containing regimen compared with chemotherapy alone. |
Potential Impact | The approval could change postoperative treatment pathways for eligible patients with stage III dMMR colon cancer. |
Key Takeaway | Roche has secured FDA approval for a Tecentriq-based adjuvant regimen in stage III dMMR colon cancer following positive Phase III ATOMIC results. |
What to Watch | Updated oncology guidelines, biomarker testing practices, clinical adoption, reimbursement and longer-term survival outcomes. |
Primary Source | Roche |
Relevant Date | 8 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires